

Biotherapies at the heart of the fight against breast cancer

October 2026

BREAST CANCER REMAINS A MAJOR GLOBAL HEALTH CHALLENGE

2,43 M

new cases

Worldwide in 2024

694 000

deaths

Worldwide in 2024

8,16 M


patients alive

diagnosed within the past 5 years




A market still dominated by mAbs and strongly shaped by biosimilars, alongside a dense clinical pipeline driven by the rise of ADCs

Marketed vs pipeline drugs



60% of marketed products are biosimilars

Clinical pipeline by phase




749 product x indication pairs
536 unique products




TNBC concentrates clinical activity, while targeting strategies diversify beyond HER2

Pipeline by tumor subtype



Main targets



ADCs are moving into earlier lines and becoming part of 1st-line combination strategies

Key players: market vs pipeline


Market leaders



Pipeline leaders



Examples of recent approvals



Sources

Epidemiological data: IARC, GLOBOCAN 2024, July 2026

Market data: GlobalData, September 2026



Discuss your needs with us at
marketstudy@mabdesign.fr